MedPath

IPACK Block After Total Knee Arthroplasty

Not Applicable
Completed
Conditions
Knee Arthropathy
Postoperative Pain
Registration Number
NCT04295421
Lead Sponsor
University Tunis El Manar
Brief Summary

Adductor canal block (ACB) is a peripheral nerve blockade technique that provides good pain control in patients undergoing total knee arthroplasty (TKA) which however does not relieve posterior knee pain. The recent technique of an ultrasound-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown promising results in providing significant posterior knee analgesia without affecting the motor nerves. The hypothesis was that the combination of ACB + IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB alone.

Detailed Description

This is a prospective, randomized and double blinded study

All patients received :

* Pregabalin 150 mg preoperatively 12 h before the surgery.

* Single-shot spinal anesthesia with 10 to 12 mg of bupivacaine 0.5% and 2.5ug sufentanil patients were randomly allocated to receive:

* Group 1: IPACK + ACB single shoot

* Group 2: contineous ACB For group 1: IPACK was realized after spinal anesthesia with 40 ml ropivacaine 0.2% All patients received ACB in the immediate postoperative period with 20 ml ropivacaine 0.2%

Post operative analgesia included:

* Paracetamol 1g IV every 6 hours

* Diclofenac sodium (50mg) 1 tablet x 2 per day

* Pregabalin 150 mg given orally once daily for a period of 4 weeks.

* PCA morphine (Patient Controlled Analgesia), as a rescue analgesia,

* Continuous ACB catheter for 48H with :

4 ml per hour 0.2% ropivacaine in group 2 4 ml per hour saline in group 1

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
88
Inclusion Criteria
  • primary total knee arthroplasty under spinal anesthesia
Exclusion Criteria
  • Contraindication or refusal to regional anesthesia
  • Contraindication to non steroidal anti inflammatory (NSAID's)
  • Allergy to opioids
  • Allergy to paracetamol
  • Creatinine clearance < 30ml/min
  • Weight<50 kg or >100kg

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Morphine consumptionDay 2

total Morphine consumption

Secondary Outcome Measures
NameTimeMethod
Pain score during mouvmentDay 2 [0=no pain ; 10=worste pain]

numerical rating scale

Pain score at restDay 2

numerical rating scale \[0=no pain ; 10=worste pain\]

Chronic painMonth 6

DN4 score \[0=minimum to 10= worste score\]

Ambulation distanceDay 2

number of steps walked by the patient

functional statusMonth 6

KOOS PS score \[0=minimum to 28= worste score\]

Trial Locations

Locations (1)

Institut Kassab D'Orthopedie

🇹🇳

Tunis, Tunisia

Institut Kassab D'Orthopedie
🇹🇳Tunis, Tunisia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.